Hyun-Mi Ju

Title: Hyun-Mi Ju: Innovator in Inflammatory Disease and Cancer Treatment

Introduction

Hyun-Mi Ju is a notable inventor based in Wonju, South Korea. He has made significant contributions to the field of medical science, particularly in the treatment of inflammatory diseases and cancer. His innovative work has led to the development of a unique polypeptide that holds promise for therapeutic applications.

Latest Patents

Hyun-Mi Ju holds a patent for "Isolated polypeptides used for treatment of inflammatory diseases and inhibiting cancer metastasis." This invention relates to a polypeptide derived from a highly conserved region of transmembrane proteins, specifically CD99 and its family members. The polypeptide has the potential to inhibit the extravasation of white blood cells and the growth and metastasis of cancer cells. Additionally, the invention includes a polynucleotide coding for the polypeptide, a vector, and a transformant transformed by the vector. Furthermore, it provides pharmaceutical compositions for preventing or treating inflammatory diseases and cancer.

Career Highlights

Hyun-Mi Ju is currently associated with Supadelixir Inc., where he continues to advance his research and development efforts. His work is characterized by a strong focus on innovative solutions for complex medical challenges.

Collaborations

Hyun-Mi Ju collaborates with esteemed colleagues, including Jang-Hee Hahn and Kyoung-Jin Lee, who contribute to his research endeavors. Their combined expertise enhances the potential impact of their work in the medical field.

Conclusion

Hyun-Mi Ju's contributions to the development of polypeptides for treating inflammatory diseases and cancer exemplify the importance of innovation in medical research. His work not only advances scientific knowledge but also holds the potential to improve patient outcomes.